Neeland, Linge, and Birkenfeld (2024), writing in Diabetes, Obesity and Metabolism , conclude that skeletal muscle changes with GLP-1 receptor agonist treatment appear adaptive: reductions in muscle volume are commensurate with what is expected given aging, disease status, and weight loss achieved, and improvements in insulin sensitivity and muscle fat infiltration likely contribute to improved muscle quality
Regulatory pathways also remain unclear, with some nanomaterials classified as medical devices and others as drugs, slowing down translation
Nontargeted identification of reactive metabolite protein adducts
The Summary of Product Characteristics (SmPC) for Ozempic, as published on the electronic medicines compendium (emc), does not list mood disturbances among the frequently reported side effects